2022
Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma
Kim A, Choi S, Park J, Kwon M, Chowdhury T, Yu H, Kim S, Kang H, Kim K, Park S, Park C, Shin E. Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma. OncoImmunology 2022, 11: 2026019. PMID: 35036078, PMCID: PMC8757477, DOI: 10.1080/2162402x.2022.2026019.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasTumor immune microenvironmentTumor-associated macrophagesM2 tumor-associated macrophagesT cellsExhausted CD8Immune cellsImmunosuppressive cellsCTLA-4Hypoxic conditionsImmunosuppressive tumor immune microenvironmentProgression-free survivalRegulatory T cellsSurvival of patientsImmunosuppressive profilePD-1Patient survivalImmune microenvironmentImmune heterogeneityHypoxia signatureCD8Different biological featuresPatientsFlow cytometrySurvival
2018
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung A, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik A, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park S, Youn J, Chowdhury T, Park C, Brem H, Pardoll D, Lim M. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology 2018, 7: e1466769. PMID: 30221069, PMCID: PMC6136875, DOI: 10.1080/2162402x.2018.1466769.Peer-Reviewed Original ResearchTumor-infiltrating dendritic cellsCervical lymph nodesTIGIT expressionT cellsTherapeutic targetEffector T cell functionDual checkpoint blockadePatient GBM samplesUnderlying immune mechanismsRegulatory T cellsTumor-infiltrating lymphocytesPoor survival outcomesNovel checkpoint inhibitorsT cell functionManagement of glioblastomaEffective treatment strategiesImmune therapeutic targetsLow-grade gliomasHuman GBM cellsMurine glioblastoma modelValuable therapeutic targetSuppressive TregsTIGIT pathwayCheckpoint inhibitorsInhibitory checkpoints